Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome Maralixibat data highlighting predictors of event-free
Source: finanznachrichten.de